Navigation Links
Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Date:10/15/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Grupo IMO of Madrid, Spain, recently hosted a symposium on the clinical use of the HiArt treatment system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Symposium speakers highlighted the HiArt system’s inherent suitability for stereotactic procedures with respect to dose conformality and homogeneity; presented clinical work on a variety of intra- and extracranial cases; and discussed future research goals.

MADISON, Wis. (Business Wire EON) October 15, 2008 -- According to Jef Van Dam, TomoTherapy EMEA General Manager: "We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners."

The 'Symposium on Tomo-Radiosurgery' included presentations from Dr. Jos Sambls, neurosurgeon and Grupo IMO president, Dr. Jos Miguel Delgado, clinical physicist and technical director for Grupo IMO, and Dr. Matthias Uhl, radiation oncologist, Heidelberg University Clinic, Heidelberg, Germany. The event was held in conjunction with the Spanish Radiosurgery Conference.

Peter Hoban, Ph.D., TomoTherapy senior product managerand medical physicist, began the program by outlining features that make the HiArt system ideal for providing stereotactic treatments: "TomoTherapy's integrated imaging and delivery platform allows one simple process to be used for both stereotactic and intensity-modulated radiation therapy (IMRT) treatments. The system clearly lends itself to a diverse range of clinical indications, as evidenced by the presentations of Drs. Sambls, Delgado and Uhl."


    Source: PRWeb
    Copyright©2008 Vocus, Inc.
    All rights reserved  

    Page: 1 2 3

    Related medicine news :

    1. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
    2. Grupo Casa Saba Announces Fourth Quarter 2007 Results
    3. Grupo Casa Saba Announces Third Quarter 2007 Results
    4. Pennsylvania Breast Cancer Coalition Hosts Annual Conference
    5. Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector
    6. Health Insurance Industry Hosts Roundtable Discussion on Health Care Reform in Albuquerque
    7. RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked: Exclusive Wine Tasting Event To Benefit Fertile Hope
    8. Alameda County Hosts National Initiative to Reduce Health Disparities
    9. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
    10. National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly
    11. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Related Image:
     Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures :  Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 
    (Date:5/4/2015)... NC (PRWEB) May 04, 2015 ... provider created a stir and showed the healthcare ... a major healthcare procedure, the downside of balance ... of a healthcare provider billing a patient for ... chooses to reimburse and what the provider chooses ...
    (Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
    (Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Hinds, Eric Gladen’s documentary Trace Amounts, and Allison Folmar, ... annual autism conference held internationally. , On Sunday, May ... Is recovery from autism possible?" Are you interested in ... You’re In There: winning our war against autism ...
    (Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
    (Date:5/3/2015)... (PRWEB) May 03, 2015 Women’s ... their Facebook page. , Their Facebook page ... many services the Practice has, it’s multiple locations, Providers ... Women’s Excellence has a very strong social media presence, ... and You Tube. , Women’s Excellence is the ...
    Breaking Medicine News(10 mins):Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4
    ... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
    ... , WASHINGTON, July 22 The ... Tobacco-Free Kids: , , The U.S. ... so-called electronic cigarettes by seeking to block importation of these products ... potential health risks of these products. The FDA announced today ...
    ... , PORTLAND, Ore., July 22 For ... originally created and produced videos developed for myRegence.com , a health ... The 30th Annual Telly Awards are widely considered to be ... from more than 14,000 entries worldwide. , , ...
    ... , , OWINGS MILLS, Md., July 22 ... MED ), our Directors, Employees and Associates are delighted that ... been nominated by President Obama, and confirmed by the U.S. Senate, as ... , Gen. McCarthy has served his country in ...
    ... SAN DIEGO, July 22 Orexigen Therapeutics, Inc. (Nasdaq: ... market and other conditions, 9,000,000 shares of its common stock in ... to grant to the underwriter a 30-day option to purchase up ... if any. All of the shares are being offered by Orexigen. ...
    ... , , MENLO PARK, Calif., July ... results for the second quarter ended July 3, 2009. , ... revenues increased 11% to $60,862,000, as compared to $54,956,000 in the second ... as compared to $50,801,000 in the second quarter of 2008. Net ...
    Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 3Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 3Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Exponent Reports Second Quarter 2009 Results 2Health News:Exponent Reports Second Quarter 2009 Results 3Health News:Exponent Reports Second Quarter 2009 Results 4Health News:Exponent Reports Second Quarter 2009 Results 5Health News:Exponent Reports Second Quarter 2009 Results 6Health News:Exponent Reports Second Quarter 2009 Results 7Health News:Exponent Reports Second Quarter 2009 Results 8Health News:Exponent Reports Second Quarter 2009 Results 9
    (Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
    (Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
    (Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
    Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
    ... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
    ... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
    Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
    Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
    Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
    10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
    0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
    Medicine Products: